Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
+1 212 318 2000
Europe, Middle East, & Africa
+44 20 7330 7500
+65 6212 1000
Noven Pharmaceuticals Inc. said Tuesday that it has reached an agreement with Shire PLC to market and sell a patch for Attention Deficit and Hyperactivity Disorder.
Noven did not disclose how much it paid for the global rights to Daytrana.
The drug was developed and manufactured by Noven but was originally licensed to Shire in 2003 and launched in the U.S. in 2006.
Shares of Shire rose 77 cents to close Tuesday at $71.18.